Navigation Links
Neurocrine Biosciences Reports First Quarter 2008 Results
Date:4/30/2008

er 31, 2007 of $276.7 million and $179.4 million, respectively. The Company expects to end 2008 with in excess of $100 million in cash and marketable securities.

"We have made significant strides in moving our GnRH program forward with three active Phase II clinical trials underway, a substantially complete preclinical package, as well as completing a commercial manufacturing and formulation process. To date we have treated approximately 500 subjects in our GnRH trials with elagolix. Elagolix has been generally safe and well tolerated with clinically meaningful reduction in endometriosis symptoms, such as dysmenorrhea, in most study participants. On the GnRH partnering front, we continue in collaboration discussions with multiple pharmaceutical companies. We will not speculate on a timeline for the completion of this deal," said Kevin Gorman, Ph.D., President and Chief Executive Officer of Neurocrine Biosciences. "Our goals for the GnRH program are to continue building value through our clinical trials and to secure the very best partner to fully develop this important asset. On the financial front, we continue to effectively manage our cash burn by prioritizing spending while advancing our pipeline."

R & D Pipeline Update

Neurocrine's clinical development group and corporate partners have five programs in clinical development and will report on R & D progress throughout 2008. Neurocrine scientists continue to supply Neurocrine's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

GnRH Antagonists for endometriosis

Elagolix in Three Phase II Clinical Trials for Endometriosis

Below is a summary of the current ongoing randomized placebo controlled Phase II trials for elagolix:

Topline

Trial Study Design Endpoints n Status Results

0603 Six-month treatment 1. I
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
4. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
5. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
6. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
7. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
8. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
9. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
10. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... TORONTO , Aug. 22, 2014 /PRNewswire/ - ... company that develops and commercializes proprietary technologies and ... it has entered into a Master Service Agreement ... their DNA-based pathogen detection assays. During the initial ... to deliver an automated working prototype of one ...
(Date:8/21/2014)... 2014 Nektar Therapeutics (NASDAQ: ... positive results from its Phase 3 pivotal clinical ... recombinant factor VIII (rFVIII) treatment for hemophilia A ... its primary endpoint in reducing annualized bleed rates ... on-demand arm. Top-line results from the ...
(Date:8/21/2014)... The Canadian Epilepsy Alliance (CEA) is thrilled to announce the ... about the most common neurological disorder in Canada ... series tells a fictional story based on the experiences of ... epilepsy. "Despite the fact that epilepsy affects ... and lack of awareness out there," says Gail Dempsey ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... DUBLIN and LEXINGTON, Massachusetts, June 24, 2011 , ... NASDAQ: SHPGY ), the global specialty,biopharmaceutical company, ... purification of,REPLAGAL ® (agalsidase alfa) drug substance at ... replacement therapy for the treatment of Fabry,disease is the ...
... , Comprehensive , F unding ... vailable in Canada, U.K. and ... scientific, technical and,medical information products and services, today announced the,expansion ... States, enabling,institutions to identify international funding opportunities. Through ...
Cached Medicine Technology:European Authorities Approve New Manufacturing Facility for Shire's REPLAGAL® (agalsidase alfa) 2European Authorities Approve New Manufacturing Facility for Shire's REPLAGAL® (agalsidase alfa) 3Elsevier's SciVal Funding Expands Globally 2Elsevier's SciVal Funding Expands Globally 3
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is a ... years. He has recently announced that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ... 2014. , GoDaddy is a popular supplier of cheap ... hosting solutions at affordable rates. It offers three Linux ... plans depend on the length of the contract. The ...
(Date:8/22/2014)... On Friday, Aug. 22, Liberty University unveiled ... , hosting a ceremony in its courtyard attended by ... public welfare. , The 162-member inaugural class of the ... joined Liberty staff, faculty, and community leaders in celebrating ... medical school. Classes began on Monday, Aug. 4. , ...
(Date:8/22/2014)... 22, 2014 Today, Zane Benefits, the ... on Account-Based Health Plans. , According to Zane Benefits, ... strategy to lower the cost of healthcare without reducing ... spending accounts, however, can be confusing. , The new ... the four main types of ABHPs. It also explains ...
(Date:8/22/2014)... (PRWEB) August 23, 2014 Top ... many famous web hosting companies and highly recommended ... customers. , The manager of Top 10 Best ... a good dedicated server hosting supplier. Actually, these ... uptime, server speed and customer support. People can ...
(Date:8/22/2014)... (PRWEB) August 23, 2014 Recently, UWDress.com, a ... outfits, has added a new range of empire bridesmaid ... the company has launched a summer promotion for these high ... discounted rates, from 25 to 75 percent off. , ... ladies. Also, UWDress.com offers efficient assistance on its website. It ...
Breaking Medicine News(10 mins):Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4Health News:FatCow Reviews Released by Top10BestSEOHosting.com 2Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2
... ... ... , ... ...
... ... ... ... ...
... induction chemotherapy followed by radiation to preserve their larynx ... half experienced no eating or swallowing problems, according to ... Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ... tracheotomy is the current standard treatment for patients with ...
... NBC News’ Tom ... ... between 1946 and 1964, a vast and prosperous group of Americans who lived through the ... hula-hoops, ate at the drive-thru and watched the Beatles play on “The Ed Sullivan Show.” ...
... ... Offer Integrated Treatment and Return-to-Work Guidelines for ,Disability and Workers’ Comp Plus New ... ... leading return-to-work experts, and The American College of Occupational and Environmental Medicine (ACOEM), ...
... ... strengthen further the technology’s position as the ultraSound choice for hospitals and long-term ... ... ultrasound-based real time locating systems for hospitals and long-term care facilities, introduced today ...
Cached Medicine News:Health News:ICMI Announces the ACCE 2010 Conference & Expo, Brings Contact Professionals Together to Improve Contact Center Performance 2Health News:ICMI Announces the ACCE 2010 Conference & Expo, Brings Contact Professionals Together to Improve Contact Center Performance 3Health News:ICMI Announces the ACCE 2010 Conference & Expo, Brings Contact Professionals Together to Improve Contact Center Performance 4Health News:ICMI Announces the ACCE 2010 Conference & Expo, Brings Contact Professionals Together to Improve Contact Center Performance 5Health News:ICMI Announces the ACCE 2010 Conference & Expo, Brings Contact Professionals Together to Improve Contact Center Performance 6Health News:Gold's Gym and Us Weekly Announce Nominees for First Ever Hollywood's Hottest Body Awards 2Health News:Gold's Gym and Us Weekly Announce Nominees for First Ever Hollywood's Hottest Body Awards 3Health News:Gold's Gym and Us Weekly Announce Nominees for First Ever Hollywood's Hottest Body Awards 4Health News:Gold's Gym and Us Weekly Announce Nominees for First Ever Hollywood's Hottest Body Awards 5Health News:Gold's Gym and Us Weekly Announce Nominees for First Ever Hollywood's Hottest Body Awards 6Health News:Gold's Gym and Us Weekly Announce Nominees for First Ever Hollywood's Hottest Body Awards 7Health News:Gold's Gym and Us Weekly Announce Nominees for First Ever Hollywood's Hottest Body Awards 8Health News:Gold's Gym and Us Weekly Announce Nominees for First Ever Hollywood's Hottest Body Awards 9Health News:Gold's Gym and Us Weekly Announce Nominees for First Ever Hollywood's Hottest Body Awards 10Health News:Gold's Gym and Us Weekly Announce Nominees for First Ever Hollywood's Hottest Body Awards 11Health News:CNBC Presents 'Tom Brokaw Reports: BOOMER$!' on Thursday, March 4th at 9PM ET/PT 2Health News:CNBC Presents 'Tom Brokaw Reports: BOOMER$!' on Thursday, March 4th at 9PM ET/PT 3Health News:Reed Group and ACOEM Renew Partnership for Return-to-Work and Treatment Guidelines 2Health News:Sonitor Technologies Announces New Staff Tag and Battery Powered Ultrasound Receiver 2
Reusable cannula with .90 mm (20 g) shaft, tapering to .30 mm (30 g). Angled 125 3 mm from tip and flattened for easy insertion into the subretinal space....
Reusable blunt cannula with luer hub. Cannula length is 32 mm....
... Flexible silicone tip cannula allows ... or hole for aspiration of ... extends 6mm beyond end of ... for easy, secure connection to ...
... Ultra thin wall .90 mm ... flow rate, available in 6 ... easy insertion through sclerotomy. 3203 ... silicone tube for infusion of ...
Medicine Products: